ENTRY       D11080                      Drug
NAME        Nemolizumab (USAN/INN);
            Nemolizumab (genetical recombination) (JAN);
            Mitchga (TN)
FORMULA     C6384H9814N1678O2034S48
EXACT_MASS  144064.2688
MOL_WEIGHT  144153.3742
SEQUENCE    (Heavy chain)
            QVQLVQSGAE VKKPGASVKV SCKASGYTFT GYIMNWVRQA PGQGLEWMGL INPYNGGTDY
            NPQFQDRVTI TADKSTSTAY MELSSLRSED TAVYYCARDG YDDGPYTLET WGQGTLVTVS
            SASTKGPSVF PLAPSSKSTS GGTAALGCLV KDYFPEPVTV SWNSGALTSG VHTFPAVLQS
            SGLYSLSSVV TVPSSNFGTQ TYTCNVDHKP SNTKVDKTVE RKSCVECPPC PAPPVAGPSV
            FLFPPKPKDT LMISRTPEVT CVVVDVSQED PEVQFNWYVD GVEVHNAKTK PREEQFNSTF
            RVVSVLTVVH QDWLNGKEYK CKVSNKGLPA PIEKTISKTK GQPREPQVYT LPPSQEEMTK
            NQVSLTCLVK GFYPSDIAVE WESNGQPENN YKTTPPMLDS DGSFFLYSKL TVDKSRWQEG
            NVFSCSVMHE ALHNHYTQKS LSLSP
            (Light chain)
            DIQMTQSPSS LSASVGDRVT ITCQASEDIY SFVAWYQQKP GKAPKLLIYN AQTEAQGVPS
            RFSGSGSGTD FTLTISSLQP EDFATYYCQH HYDSPLTFGG GTKVEIKRTV AAPSVFIFPP
            SDEQLKSGTA SVVCLLNNFY PREAKVQWKV DNALQSGNSQ ESVTEQDSKD STYSLSSTLT
            LSKADYEKHK VYACEVTHQG LSSPVTKSFN RGEC
            (Disulfide bridge: H22-H96, H148-H204, H224-L214, H227-h227, H230-h230, H261-H321, H367-H425, h22-h96, h148-h204, h224-l214, h261-h321, h367-h425, L23-L88, L134-L194, l23-l88, l134-l194)
  TYPE      Peptide
CLASS       Immunological agent
             DG02019  Interleukin inhibitor
            Dermatological agent
             DG03243  Atopic dermatitis agent
REMARK      Therapeutic category: 4490
            Product: D11080<JP>
EFFICACY    Anti-inflammatory, Antipruritic, Anti-IL-31 receptor antibody
  TYPE      Monoclonal antibody
COMMENT     Treatment of atopic dermatitis (AD), treatment of prurigo nodularis (PN) and chronic kidney disease associated pruritus (CKD-aP)
TARGET      IL31RA [HSA:133396] [KO:K22630]
  PATHWAY   hsa04060(133396)  Cytokine-cytokine receptor interaction
BRITE       Therapeutic category of drugs in Japan [BR:br08301]
             4  Agents affecting cellular function
              44  Allergic agents
               449  Miscellaneous
                4490  Miscellaneous
                 D11080  Nemolizumab (USAN/INN); Nemolizumab (genetical recombination) (JAN)
            Drug groups [BR:br08330]
             Immunological agent
              DG02019  Interleukin inhibitor
               D11080  Nemolizumab
             Dermatological agent
              DG03243  Atopic dermatitis agent
               D11080  Nemolizumab
            Drug classes [BR:br08332]
             Immunological agent
              DG02019  Interleukin inhibitor
               D11080  Nemolizumab
             Dermatological agent
              DG03243  Atopic dermatitis agent
               D11080  Nemolizumab
            Target-based classification of drugs [BR:br08310]
             Cytokines and receptors
              Cytokine receptors
               Interleukin receptors
                IL31RA
                 D11080  Nemolizumab (USAN/INN) &lt;JP&gt;
            New drug approvals in Japan [br08318.html]
             Drugs with new active ingredients
              D11080
            New drug approvals in the USA, Europe and Japan [br08328.html]
             Approval dates by FDA, EMA and PMDA
              D11080
DBLINKS     CAS: 1476039-58-3
            PubChem: 375581027
///
